Advances for Medical Professionals

Advances for Medical Professionals

Medical News for Patients & Visitors

Medical News for Patients & Visitors

Outcomes & Quality Reports

Outcomes & Quality Reports

246

Advances in Urology

NewYork-Presbyterian

Advances in Urology

The Upward Trajectory of Robotic-Assisted Radical Cystectomy

Dr. Scherr

Douglas S. Scherr, MD

Robotic-assisted radical cystectomy has assumed its rightful place in the skill set of urologic oncologists. The application of robotics to perform radical cystectomy has been steadily increasing since its introduction nearly two decades ago. Urologic oncologists in the Department of Urology at NewYork-Presbyterian/Weill Cornell Medical Center were among the earliest adopters of the procedure and, having accumulated unparalleled experience in the field, continue to refine the techniques and technology that address the morbidities of open surgery.

In a comprehensive review of robotic radical cystectomy in today’s management of bladder cancer, Douglas S. Scherr, MD, Clinical Director of Urologic Oncology, and Weill Cornell Medicine urologic faculty detail the many aspects of the approach – from patient selection to oncologic outcomes – that facilitate its success in treating patients with bladder cancer.

Latitude in Patient Selection

Studies have shown that no major differences exist in evaluating patients for either robotic or open procedures for radical cystectomy, although consensus guidelines include a number of co-morbidities that should be considered in decision-making. These include obesity, extravesical disease, previous vascular surgery, or preexisting cardiopulmonary disease that could be affected by positioning.

Shorter Hospital Stays

Robotic procedures are associated with hospitalizations 2.5 days shorter than open surgery. Although not validated, this shorter length of stay may be related to a number of factors, including the increasing adoption of ERAS protocols, using a minimally invasive approach, fewer perioperative transfusions, and proficiency of the surgeon.

Comparable and Favorable Outcomes

Both robotic and open surgery have been shown to have similar oncologic outcomes in terms of time to recurrence, cancer-specific survival, and overall survival. Additionally, a recent meta-analysis in randomized and nonrandomized comparative studies found that complication rates between the two approaches within 90 days were also comparable. Postoperative quality-of-life scores were analogous at 3 and 6 months post-procedure. The general consensus remains that robotic procedures result in significantly less blood loss, with nearly all trials that have included blood loss data indicating an average decrease of approximately 400 mL of blood loss compared with open surgery.

Experience Counts

In general, there is consensus among experts that experience level is an important factor in reaching an acceptable degree of competence. It is recommended that surgeons perform their first 20 to 30 robotic-assisted ileal conduit reconstructions and first 100 robotic-assisted neobladder or continent reconstruction cases under the supervision of an experienced mentor to be considered a proficient robotic surgeon.

Read More

Cai PY, Khan AI, Shoag JE, Scherr DS. Robotic radical cystectomy in the contemporary management of bladder cancer. The Urologic Clinics of North America. 2021 Feb;48(1):45-50.

Related Publications


NewYork-Prebsyterian logo
Urology & Oncology

Bladder Cancer: Therapeutic Trio Offers Potential Alternative to Radical Cystectomy

Patients with Bacillus Calmette-Guerin (BCG)-unresponsive bladder cancer remain a challenging patient population to treat. Radical cystectomy continues as the oncologic gold standard treatment in patients at high risk of recurrence after BCG failure in non-muscle-invasive bladder cancer.

Related Publications